AbbVie Inc (ABBV) 8-K Current Report: February 26, 2026
Filed: February 26, 2026
Health Care
Pharmaceutical PreparationsAbbVie Inc (ABBV) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
AbbVie Inc 8-K Feb 26, 2026 Event Analysis
Item 8.01 · Other Events
- • Total debt issuance $8B across 7 tranches, ranging from floating rate to 40-year notes (2066), closing March 4, 2026
- • Net proceeds ~$7.95B; $2B earmarked to repay 364-day term loan maturing May 2026, remainder for general corporate/debt purposes
- • Fixed coupon rates: 3.775% (2028), 4.125% (2031), 4.400% (2033), 4.750% (2036), 5.550% (2056), 5.650% (2066) — signals AbbVie locking in long-term capital at current rates
- • Largest tranches: $1.5B each in 2028 and 2036 Notes, suggesting preference for near- and medium-term maturities
- • Significant leverage signal: $8B raise well exceeds the $2B term loan obligation, implying substantial additional debt refinancing or strategic spend ahead
Other AbbVie Inc 8-K Filings
Get deeper insights on AbbVie Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.